(Reuters) - There were no cases of severe allergic reactions to Pfizer Inc and partner BioNTech SE's COVID-19 vaccine candidate during clinical trials, a Pfizer executive said at a regulatory ...

In an Untitled Letter, regulators said Facebook promotions for Pfizer’s lymphoma therapy overstated its approved use and ...

NEW YORK (Reuters) - The U.S. Food and Drug Administration is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE's COVID-19 vaccine in ...

"The public understandably has been concerned about reports of rare, severe allergic reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines," Dr. Anthony Fauci, director of the National ...

The National Institutes of Health is reportedly planning to conduct a clinical study to determine why people are having severe allergic reactions to Pfizer's COVID-19 vaccine. According to the ...

The company has increased its payouts over the past five years despite significant challenges.

Pfizer (PFE) fell ~5% on Tuesday as Wall Street analysts assessed mid-stage data the company posted for its obesity therapy PF-08653944 ahead of its consensus-beating Q4 2025 results, which indicated ...

・The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3. ・Pfizer’s BioNTech position was reduced by 54.7%, leaving ...